Experimental approaches to treating prostate cancer with TRT, explored at the preclinical stage, include using different prostate-specific membrane antigen (PSMA) ligands, radionuclides, or targeting other receptors upregulated on prostate cancer cells (23, 58–60). Here, FOLH1 is linked to prostate carcinoma.